Objective: to analyze the clinical efficacy of etacridine combined with mifepristone (MFP) in the treatment of induced labor during middle pregnancy. Methods: from May 2015 to April 2020, 50 patients with midterm preg...Objective: to analyze the clinical efficacy of etacridine combined with mifepristone (MFP) in the treatment of induced labor during middle pregnancy. Methods: from May 2015 to April 2020, 50 patients with midterm pregnancy during labor induction period in our hospital were selected. The digital table was randomly divided into two groups with 25 cases in each group. Treatment was given to patients from a single drug group. The etazidine-bound group was treated with etazidine, acridine combined with MFP. The time, success rate, and incidence of complications were compared between the two groups from the start of dosing to embryo excretion. Results: the duration from initial administration to embryo expulsion in combination group was 36.21±2.45h shorter than that in single drug group, 56.13±5.01h, P < 0.05. The combined power was 100.00% higher than that of the single drug group (76.00%, P < 0.05). There were no serious complications in the two groups, including 2 cases of low fever in the monotherapy group and 3 cases of mild diarrhea and nausea in the combination group (P > 0.05). Conclusion: the clinical effect of ethacridine combined with MFP in the treatment of induced labor in the second trimester is better than ethacridine, which can improve the success rate and shorten the time of induced labor, with high safety.展开更多
文摘Objective: to analyze the clinical efficacy of etacridine combined with mifepristone (MFP) in the treatment of induced labor during middle pregnancy. Methods: from May 2015 to April 2020, 50 patients with midterm pregnancy during labor induction period in our hospital were selected. The digital table was randomly divided into two groups with 25 cases in each group. Treatment was given to patients from a single drug group. The etazidine-bound group was treated with etazidine, acridine combined with MFP. The time, success rate, and incidence of complications were compared between the two groups from the start of dosing to embryo excretion. Results: the duration from initial administration to embryo expulsion in combination group was 36.21±2.45h shorter than that in single drug group, 56.13±5.01h, P < 0.05. The combined power was 100.00% higher than that of the single drug group (76.00%, P < 0.05). There were no serious complications in the two groups, including 2 cases of low fever in the monotherapy group and 3 cases of mild diarrhea and nausea in the combination group (P > 0.05). Conclusion: the clinical effect of ethacridine combined with MFP in the treatment of induced labor in the second trimester is better than ethacridine, which can improve the success rate and shorten the time of induced labor, with high safety.
